Alpha L-Iduronidase Market 2021 Share, Growth and Regional Forecast
ReportsWeb.com published “Alpha L-Iduronidase - Pipeline Review H1 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months.
(EMAILWIRE.COM, October 04, 2017 ) ReportsWeb.com published “Alpha L-Iduronidase - Pipeline Review H1 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months.
Original Content:
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Alpha L-Iduronidase - Pipeline Review, H1 2017, outlays comprehensive information on the Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.
For more information about this report: http://www.reportsweb.com/alpha-l-iduronidase-pipeline-review-h1-2017
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Alpha L-iduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I (MPS I) . The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) .
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Alpha L-Iduronidase (IDUA or EC 3.2.1.76)
- The report reviews Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001834418/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha L-Iduronidase (IDUA or EC 3.2.1.76)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha L-Iduronidase (IDUA or EC 3.2.1.76) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by AngioChem Inc, H1 2017
Pipeline by ArmaGen Inc, H1 2017
Pipeline by Bioasis Technologies Inc, H1 2017
Pipeline by Immusoft Corp, H1 2017
Pipeline by RegenxBio Inc, H1 2017
Pipeline by Sangamo Therapeutics Inc, H1 2017
Dormant Projects, H1 2017
List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
Inquire before Buying at http://www.reportsweb.com/buy&RW0001834418/buy/3500
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
Original Content:
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Alpha L-Iduronidase - Pipeline Review, H1 2017, outlays comprehensive information on the Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.
For more information about this report: http://www.reportsweb.com/alpha-l-iduronidase-pipeline-review-h1-2017
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Alpha L-iduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I (MPS I) . The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) .
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Alpha L-Iduronidase (IDUA or EC 3.2.1.76)
- The report reviews Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001834418/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha L-Iduronidase (IDUA or EC 3.2.1.76)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha L-Iduronidase (IDUA or EC 3.2.1.76) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by AngioChem Inc, H1 2017
Pipeline by ArmaGen Inc, H1 2017
Pipeline by Bioasis Technologies Inc, H1 2017
Pipeline by Immusoft Corp, H1 2017
Pipeline by RegenxBio Inc, H1 2017
Pipeline by Sangamo Therapeutics Inc, H1 2017
Dormant Projects, H1 2017
List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
Inquire before Buying at http://www.reportsweb.com/buy&RW0001834418/buy/3500
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results